Publications by authors named "Alexander David James"
Article Synopsis
- Iptacopan (LNP023) is an orally-administered potent drug designed to inhibit factor B in the alternative complement pathway, currently being developed for conditions like paroxysmal nocturnal hemoglobinuria.
- A study examining the absorption, distribution, metabolism, and excretion (ADME) of Iptacopan in six healthy volunteers found it to be 71% absorbed with a peak concentration reached in 1.5 hours and a plasma half-life of 12.3 hours.
- The elimination of Iptacopan is primarily through liver metabolism, with findings showing a significant amount excreted in feces (71.5%) and urine (24.8%), indicating low systemic exposure to potentially
1. Leniolisib is a novel oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor, currently in clinical development for the treatment of inflammatory and autoimmune diseases. 2.
View Article and Find Full Text PDFThe human mass balance study is the definitive study for the assessment of absorption, distribution, metabolism, and excretion (ADME) properties of a new chemical entity in humans. Traditionally this has been carried out by the administration of radiolabeled drug substances, typically C or occasionally H, as detection methods for these isotopes allow the absolute quantification of drug-related material (DRM) in blood, plasma, and excreta. Coupled with the use of analytical techniques such as liquid chromatography-mass spectrometry, a picture of the metabolic fate of a compound can be elucidated.
View Article and Find Full Text PDFIn Africa, Sutherlandia frutescens is a popular medicinal herb widely consumed by people living with human immunodeficiency virus/AIDS. Concomitant use with antiretroviral drugs has generated concerns of herb-drug interaction (HDI). This study investigated the inhibitory effects of the crude extracts of S.
View Article and Find Full Text PDF